【how to cure marijuana in mason jar】Evotec to Attend Upcoming Investor Conferences
HAMBURG,how to cure marijuana in mason jar GERMANY / ACCESSWIRE / November 4, 2020 /
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at and attending the following upcoming conferences until the end of 2020:
Consilium Strategic Communications 8
th
Annual Healthcare Conference
Date
:
Monday, 16 November 2020
Venue
:
Virtual
Attendee
:
Enno Spillner, Chief Financial Officer
German Equity Forum
Date
:
Monday, 16 November 2020
,
Presentation: 16 November 2020, 2.00 pm (CET)
Venue
:
Virtual
Attendee
:
Dr Werner Lanthaler, Chief Executive Officer
Jefferies London Healthcare Conference
Date
:
Tuesday, 17 November 2020
and Thursday, 19 November 2020
,
Presentation: 19 November 2020, 8.20 am (CET)
Venue
:
Virtual
Attendee
:
Enno Spillner, Chief Financial Officer
Kempen's 17
th
London Conference
Date
:
Tuesday, 24 November 2020
Venue
:
Virtual
Attendee
:
Dr Werner Lanthaler, Chief Executive Officer
Structured FINANCE Digital Week
Date
:
Wednesday, 25 November 2020
Venue
:
Virtual
Attendee
:
Enno Spillner, Chief Financial Officer
18
th
Berenberg European Conference
Date
:
Wednesday, 02 December 2020
,
Presentation: 02 December 2020, 4.00 pm (CET)
Venue:
Virtual
Attendee
:
Dr Werner Lanthaler, Chief Executive Officer
ABOUT EVOTEC SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,400 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to
www.evotec.com
and follow us on Twitter
@Evotec
.
FORWARD-LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
IR Contact Evotec SE:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775,
Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255,
SOURCE:
Evotec AG via EQS Newswire
View source version on accesswire.com:
https://www.accesswire.com/614415/Evotec-to-Attend-Upcoming-Investor-Conferences
View comments
(责任编辑:Leisure)
- ·Wells Fargo CEO tells Congress bank has doubled down on regulatory issues
- ·U.S. Dollar Index (DX) Futures Technical Analysis – Overtaking 97.470 Could Trigger Surge into 97.920
- ·Analysts Just Slashed Their China Cinda Asset Management Co., Ltd. (HKG:1359) EPS Numbers
- ·Have Insiders Been Buying IKONICS Corporation (NASDAQ:IKNX) Shares?
- ·South African drugmaker Aspen sees no immediate impact of India's decision to curb drug exports
- ·EPR Properties: 3Q Earnings Snapshot
- ·Rackspace Technology Among the First to Support the Launch of Professional Services in AWS Marketplace, Announces New Professional Services & Solutions at AWS re:Invent 2020
- ·Market Sentiment Improves As Investors Pin Hopes on G7 Action
- ·UPLCQ Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Ultra Petroleum Corp. Investors of Class Action and Lead Plaintiff Deadline: November 2, 2020
- ·Is Wanda Sports Group (WSG) A Good Stock To Buy Now?
- ·Why SkiStar AB (publ)'s (STO:SKIS B) High P/E Ratio Isn't Necessarily A Bad Thing
- ·Oil's Recovery Could Take Decades, Not Years
- ·Imagine Owning ImmunoPrecise Antibodies (CVE:IPA) And Wondering If The 44% Share Price Slide Is Justified
- ·Can Ero Copper Corp. (TSE:ERO) Maintain Its Strong Returns?
- ·EMERGING MARKETS-Latam stocks weaken as risk rally pauses
- ·How Much is Wisdom Education International Holdings Company Limited's (HKG:6068) CEO Getting Paid?
- ·Tap These 5 Bargain Stocks With Enticing EV/EBITDA Ratios
- ·Gatling Discovers 3rd High-Grade Gold Trend at Kir Vit; Encounters Highest Grades to Date
- ·The Global Military Ground Robot Market is expected to grow by $ 42.08 bn during 2020-2024 progressing at a CAGR of 27% during the forecast period
- ·The Returns At Treatt (LON:TET) Provide Us With Signs Of What's To Come